# US 2016/0354342 A1 · Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor.

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354342 A1
- Document ID: US20160354342A1
- Status: Published application
- Kind: A1
- Application number: 15/242,852
- Filed: 2016-08-22
- Published: 2016-12-08
- Earliest claimed: 2014-02-25
- Inventors: Muslim D. Shahid
- Web page: https://patentgrep.com/patent/US20160354342A1

## CPC

- A61K 31/385: having two or more sulfur atoms in the same ring
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A treatment for acid related gastrointestinal disorders. The methods and compounds described include gastric acid secretion inhibitors in combination with alpha lipoic acid (ALA) or related compounds. ALA is not known as a treatment for acid related gastrointestinal disorders; however, when combined with certain compounds used in the treatment of acid related gastrointestinal disorders, ALA significantly improves existing treatments.

## Claims

### Claim 1

A method of treating acid related gastrointestinal disorders comprising:
administering orally at an effective daily dose a mixture of between 10 mg and 1500 mg of a dithiolane compound and/or one or more modified derivatives thereof, and between 25 mg and 800 mg of an H2 receptor antagonist and/or one or more modified derivatives thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein the dithiolane compound and/or one or more modified derivatives thereof and the H2 receptor antagonist and/or one or more modified derivatives thereof are orally administered prior to consuming food.

### Claim 3 (depends on 1)

The method of claim 1 wherein the dithiolane compound and/or one or more modified derivatives thereof and the H2 receptor antagonist and/or one or more modified derivatives thereof is administered such that a significant amount of the dithiolane compound and/or one or more modified derivatives thereof and the H2 receptor antagonist and/or one or more modified derivatives thereof are able to exert a significant biological effect in the body.

### Claim 4 (depends on 1)

The method of claim 1 wherein the dithiolane compound and/or one or more modified derivatives thereof and the H2 receptor antagonist and/or one or more modified derivatives thereof are combined prior to administration.

### Claim 5 (depends on 1)

The method of claim 1 wherein the dithiolane compound and/or one or more modified derivatives thereof and the H2 receptor antagonist and/or one or more modified derivatives thereof are combined in pill form, liquid form or related means of oral ingestion.

### Claim 6 (depends on 1)

The method of claim 1 wherein the dithiolane compound is 1,2-dithiolane-3-pentanoic acid and/or one or more modified derivatives thereof.

### Claim 7 (depends on 1)

The method of claim 1 wherein the dithiolane compound is the R enantiomer of 1,2-dithiolane-3-pentanoic acid with the structure
and/or one or more modified derivatives thereof.

### Claim 8 (depends on 1)

The method of claim 1 wherein the dithiolane compound is selected from the group consisting of 1,2 ditholane, 1,3 dithiolane, 1,4 dithiolane, and 1,5, dithiolane, and 1,6 dithiolane, 1,2-dithiolane-3-pentanoic acid, dihydrolipoic acid, bisnorlipoic acid, 6,8-bismethylthio-octanoic acid, tetranorlipoic acid, 4,6-bismethylthio-hexanoic acid, and 2,4-bismethylthio-butanoic acid.

### Claim 9 (depends on 6)

The method of claim 6 wherein said 1,2-dithiolane-3-pentanoic acid and/or one or more modified derivatives thereof includes an alkali metal or alkaline-earth metal salt of 1,2-dithiolane-3-pentanoic acid.

### Claim 10 (depends on 1)

The method of claim 1 wherein the dithiolane compound is represented by formula I or II,
wherein, n is an integer from to 1 to 9; wherein X is an alkyl, alkene, alkyne, aryl, alkylaryl or alkylaryl; wherein (R) is CH2 or CHCH; wherein y is an integer from 1 to 20; wherein Z is COOH or COOR1; wherein R1 is an alkyl, alkene, alkyne, aryl, alkylaryl, alkylaryl, alkylphosphate, alkylphosphite, arylphospate, arylphosphite, alkyl sulfate, aryl sulfate, alkylaryl sulfate, alkyl sulfite, aryl sulfite, alkyl aryl sulfite, arylamine, pyrimidine, imidazoline, purine, hydrogen, alkyl, halogen, cyano, carboxy, carboxyalkyl, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoyloxy, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl and acyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl, alkylsulphonyl, F, CL, Br, P, S, NO, NO3, NO2, SO, SO2, NH2, NNH, NO3, NO2, PO4, P03, POOR2, POR2R2, SR2R2, SOR2, NNR2, NHR2, or NR2R2; wherein R2 is hydrogen, alkyl, alkene, alkyne, aryl, alkylaryl, alkylaryl, alkylphosphate, alkylphosphite, arylphospate, arylphosphite, alkylsulfate, arylsulfate, alkylaryl sulfate, alkyl sulfite, aryl sulfite, alkyl aryl sulfite, arylamine, pyrimidine, imidazoline, purine, alkyl, halogen, cyano, carboxy, carboxyalkyl, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoyloxy, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl and acyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl, or alkyl sulphonyl.

### Claim 11 (depends on 1)

The method of claim 1 wherein the H2 receptor antagonist is an ethenediamine compound and/or one or more modified derivatives thereof.

### Claim 12 (depends on 11)

The method of claim 11 wherein the ethenediamine compound and/or one or more modified derivatives thereof is selected from a group consisting of Ranitidine HCl, Nizatidine, Famotidine, Cimetidine, -[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]-ethyl]-N′-methylthiourea, N-cyano-N′-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N″-methylguanidine, N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-1,1-ethenediamine, N-cyano-N′-[2-[[[5-(methylamino)methyl-2-furanyl]methyl]thio]-ethyl]-N″-methylguanidine, N-[2-[[[5-(diethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-1,1-ethenediamine, N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N′-(2-methoxyethyl)-2-nitro-1,1-ethenediamine, N-[2-[[[5-(methylamino)methyl-2-furanyl]methyl]thio]ethyl]-N-methyl-2-nitro-1,1-ethenediamine, N-[3-[[5-(dimethylamino)methyl-2-furanyl]thio]propyl]-N′-methyl-2-nitro-1,1-ethenediamine, N-[2-[[[5-(ethylmethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-1,1-ethenediamine, N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N′-nitroguanidine, N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N′-methanesulphonyl-N″-methylguanidine, N-[4-[5-(dimethylamino)methyl-2-furanyl]butyl]-N′-methyl-thiourea, N-benzenesulphonyl-N′-[2-[[[5-(dimethylamino)methyl-2-furanyl]-methyl]thio]ethyl]-N″-methylguanidine, N-[5-[5-(dimethylamino)methyl-2-furanyl]pentyl]-N′-methyl-2-nitro-1,1-ethenediamine, N-cyano-N′-[5-[5-(dimethylamino)methyl-2-furanyl]pentyl]-N′-methylguanidine, N-[4-[5-(dimethylamino)methyl-2-furanyl]butyl]-N′-methyl-2-nitro-1,1-ethenediamine, N-cyano-N′-[4-[5-(dimethylamino)methyl-2-furanyl]butyl]-N″-methylguanidine, N-[2-[[[5-[3-[dimethylamino]propyl]-2-furanyl]methyl]thio]-ethyl]-N′-methyl-2-nitro-1,1-ethenediamine, and N-[2-[[[5-[[2-(dimethylamino)ethyl]amino]methyl-2-furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-1,1-ethenediamine.

### Claim 13 (depends on 1)

The method of claim 1 wherein the dithiolane compound and/or one or more modified derivatives thereof and the H2 receptor antagonist and/or one or more modified derivatives thereof are orally administered after consuming food.

### Claim 14

A method of treating acid related gastrointestinal disorders comprising:
administering a therapeutically effective amount a mixture of a dithiolane compound and/or one or more modified derivatives thereof, and an H2 receptor antagonist and/or one or more modified derivatives thereof.

### Claim 15 (depends on 14)

The method of claim 14 further comprising administering orally at an effective daily dose a mixture of between 100 mg and 1500 mg of a dithiolane compound and/or one or more modified derivatives thereof, and between 50 mg and 600 mg of the H2 receptor antagonist and/or one or more modified derivatives thereof.

### Claim 16

A method of treating acid related gastrointestinal disorders comprising:
administering a therapeutically effective amount a mixture of a dithiolane compound and/or one or more modified derivatives thereof, and an H2 receptor antagonist and/or one or more modified derivatives thereof.
